Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir □) in advanced HIV infection

Abstract

Objectives: To assess the efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine; GPO-vir □ in advanced HIV infection. Material and Method: Open-label combined prospective and retrospective study involving 102 HIV infected patients with baseline CD4cell count < 100 cells/mm 3. All patients received GPO-vir □ for 48 weeks. The CD4 cell count and plasma viral load (pVL) was measured at 48 weeks. Results: The median baseline CD4 cell count and pVL were 13 cells/mm 3 and 363,500 copies/ml, respectively. At 48 weeks, the median CD4 cell count increased to191 cells/mm 3 and 63.7% in intention-to treat and 82.3% in on-treatment analysis had pVL < 50 copies/ml. There was no significant difference in pVL between patients with baseline pVL > 100,000 or ≤ 100,000 copies/ml (p = 0.312). The incidence of hepatotoxicity, rash and peripheral neuropathy was 4.9%, 14.7% and 6.9%, respectively. Conclusion: GPO-vir □ was well tolerated and effective in increasing CD4 cell count and suppressing plasma viremia in advanced HIV infection during the 48 weeks follow-up period.